Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous tumor stem cell mRNA-transfected dendritic cells
- Development stage
- Phase 3
- Lead developer
- Oslo University Hospital
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
Autologous tumor stem cell mRNA-transfected dendritic cells are a personalized cancer immunotherapy that combines patient-derived dendritic cells with messenger RNA encoding antigens from the patient's own tumor stem cells. The therapeutic approach involves harvesting tumor tissue from individual patients, isolating cancer stem cells, amplifying mRNA from these cells, and transfecting the mRNA into autologous monocyte-derived dendritic cells through electroporation. These engineered dendritic cells are then administered intradermally to activate patient-specific T-cell immune responses against the tumor stem cell population. The mechanism leverages the dendritic cells' role as antigen-presenting cells to educate the immune system to recognize and attack cancer stem cells, which are believed to drive tumor progression and recurrence. This approach has been investigated primarily in glioblastoma multiforme, with early clinical trials demonstrating safety, immunogenicity, and evidence of prolonged progression-free survival compared to matched controls.
- Brand names
- None identified
- Other names
- Autologous cancer stem cell mRNA transfected dendritic cellsDendritic cell immunotherapy against cancer stem cellsmRNA-transfected autologous dendritic cells targeting tumor stem cells
Beyond the preview
Go deeper on Autologous tumor stem cell mRNA-transfected dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous tumor stem cell mRNA-transfected dendritic cells.